Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

c-Fos oncogene regulator Elk-1 interacts with BRCA1 splice variants BRCA1a/1b and enhances BRCA1a/1b-mediated growth suppression in breast cancer cells

Abstract

Elk-1, a c-Fos protooncogene regulator, which belongs to the ETS-domain family of transcriptional factors, plays an important role in the induction of immediate early gene expression in response to a variety of extracellular signals. In this study, we demonstrate for the first time the in vitro and in vivo interaction of Elk-1 with BRCA1 splice variants BRCA1a and BRCA1b using GST-pull down assays, co-imunoprecipitations/Western blot analysis of cell extracts from breast cancer cells and mammalian two-hybrid assays. We have localized the BRCA1 interaction domain of Elk-1 protein to the conserved ETS domain, a motif involved in DNA binding and protein–protein interactions. We also observed binding of BRCA1 proteins to other ETS-domain transcription factors SAP1, ETS-1, ERG-2 and Fli-1 but not to Elk-1 splice variant ΔElk-1 and c-Fos protooncogene. Both BRCA1a and BRCA1b splice variants function as growth suppressors of human breast cancer cells. Interestingly, our studies reveal that although both Elk-1 and SAP-1 are highly homologous members of a subfamily of ETS domain proteins called ternary complex factors, it is only Elk-1 but not SAP-1 that can augment the growth suppressive function of BRCA1a/1b proteins in breast cancer cells. Thus Elk-1 could be a potential downstream target of BRCA1 in its growth control pathway. Furthermore, we have observed inhibition of c-Fos promoter activity in BRCA1a transfected stable breast cancer cells and over expression of BRCA1a/1b attenuates MEK-induced SRE activation in vivo. These results demonstrate for the first time a link between the growth suppressive function of BRCA1a/1b proteins and signal transduction pathway involving Elk-1 protein. All these results taken together suggest that one of the mechanisms by which BRCA1a/1b proteins function as growth/tumor suppressors is through inhibition of the expression of Elk-1 target genes like c-Fos.

This is a preview of subscription content

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

References

  • Abate C, Luk D, Curran T . 1991 Mol. Cell. Biol. 11: 3624–3632

  • Anderson SF, Schlegel BP, Nakajima T, Wolpin ES, Parvin JD . 1998 Nat. Genet. 19: 254–256

  • Bhattacharya G, Lee L, Reddy ES, Rao VN . 1993 Oncogene 8: 3459–3464

  • Bork P, Hofmann K, Bucher P, Neuwald AF, Altschul SF, Koonin EV . 1997 FASEB J. 11: 68–76

  • Brugarolas J, Jacks T . 1997 Nat. Med. 3: 721–722

  • Callebaut I, Mornon JP . 1997 FEBS Lett. 400: 25–30

  • Chai YL, Cui J, Shao N, Shyam E, Reddy P, Rao VN . 1999 Oncogene 18: 263–268

  • Chapman MS, Verma IM . 1996 Nature 382: 678–679

  • Chen J, Silver DP, Walpita D, Cantor SB, Gazdar AF, Tomlinson G, Couch FJ, Weber BL, Ashley T, Livingston DM, Scully R . 1998 Mol. Cell. 2: 317–328

  • Couch FJ, Weber BL . 1996 Hum. Mutat. 8: 8–18

  • Cui JQ, Shao N, Chai Y, Wang H, Reddy ES, Rao VN . 1998a Oncol. Rep. 5: 591–595

  • Cui JQ, Wang H, Reddy ES, Rao VN . 1998b Oncol. Rep. 5: 585–589

  • Dalton S, Treisman R . 1992 Cell 68: 597–612

  • Drewett V, Muller S, Goodall J, Shaw PE . 2000 J. Biol. Chem. 275: 1757–1762

  • Easton DF, Ford D, Bishop DT . 1995 Am. J. Hum. Genet. 56: 265–271

  • Fan S, Wang JA, Yuan RQ, Ma YX, Meng Q, Erdos MR, Brody LC, Goldberg ID, Rosen EM . 1998 Oncogene 16: 3069–3082

  • Ford D, Easton DF, Peto J . 1995 Am. J. Hum. Genet. 57: 1457–1462

  • Giovane A, Pintzas A, Maira SM, Sobieszczuk P, Wasylyk B . 1994 Genes. Dev. 8: 1502–1513

  • Gupta S, Barrett T, Whitmarsh AJ, Cavanagh J, Sluss HK, Derijard B, Davis RJ . 1996 EMBO J. 15: 2760–2770

  • Hill CS, Marais R, John S, Wynne J, Dalton S, Treisman R . 1993 Cell 73: 395–406

  • Hipskind RA, Rao VN, Mueller CG, Reddy ES, Nordheim A . 1991 Nature 354: 531–534

  • Holt JT, Thompson ME, Szabo C, Robinson-Benion C, Arteaga CL, King MC, Jensen RA . 1996 Nat. Genet. 12: 298–302

  • Humphrey JS, Salim A, Erdos MR, Collins FS, Brody LC, Klausner RD . 1997 Proc. Natl. Acad. Sci. USA 94: 5820–5825

  • Jensen DE, Proctor M, Marquis ST, Gardner HP, Ha SI, Chodosh LA, Ishov AM, Tommerup N, Vissing H, Sekido Y, Minna J, Borodovsky A, Schultz DC, Wilkinson KD, Maul GG, Barlev N, Berger SL, Prendergast GC, Rauscher 3rd FJ . 1998 Oncogene 16: 1097–1112

  • Katsama A, Sourvinos G, Zachos G, Spandidos DA . 2000 Cancer Lett. 150: 165–170

  • Koonin EV, Altschul SF, Bork P . 1996 Nat. Genet. 13: 266–268

  • Lane TF, Deng C, Elson A, Lyu MS, Kozak CA, Leder P . 1995 Genes. Dev. 9: 2712–2722

  • Lopez M, Oettgen P, Akbarali Y, Dendorfer U, Libermann TA . 1994 Mol. Cell. Biol. 14: 3292–3309

  • Lu M, Conzen SD, Cole CN, Arrick BA . 1996 Cancer Res. 56: 4578–4581

  • Marais R, Wynne J, Treisman R . 1993 Cell 73: 381–393

  • Marquis ST, Rajan JV, Wynshaw-Boris A, Xu J, Yin GY, Abel KJ, Weber BL, Chodosh LA . 1995 Nat. Genet. 11: 17–26

  • Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, Bell R, Rosenthal J, Hussey C, Tran T, McClure M, Frye C, Hattier T, Phelps R, Haugen-Strano A, Katcher H, Yakumo K, Gholami Z, Shaffer D, Stone S, Bayer S, Wray C, Bogden R, Dayananth P, Ward J, Tonin P, Narod S, Bristow PK, Norris FH, Helvering L, Morrison P, Rosteck P, Lai M, Barrett T . 1994 Science 266: 66–71

  • Monteiro AN, August A, Hanafusa H . 1996 Proc. Natl. Acad. Sci. USA 93: 13595–13599

  • Nozaki M, Onishi Y, Kanno N, Ono Y, Fujimura Y . 1996 DNA. Cell. Biol. 15: 855–862

  • Ozcelik H, To MD, Couture J, Bull SB, Andrulis IL . 1998 Int. J. Cancer 77: 1–6

  • Price MA, Rogers AE, Treisman R . 1995 EMBO J. 14: 2589–2601

  • Rao VN, Huebner K, Isobe M, ar-Rushdi A, Croce CM, Reddy ES . 1989 Science 244: 66–70

  • Rao VN, Ohno T, Prasad DD, Bhattacharya G, Reddy ES . 1993 Oncogene 8: 2167–2173

  • Rao VN, Papas TS, Reddy ES . 1987 Science 237: 635–639

  • Rao VN, Reddy ES . 1992 Oncogene 7: 2335–2340

  • Rao VN, Reddy ES . 1993 Cancer Res. 53: 215–220

  • Rao VN, Shao N, Ahmad M, Reddy ES . 1996 Oncogene 12: 523–528

  • Reddy ES, Rao VN . 1990 Cancer Res. 50: 5013–5016

  • Scully R, Anderson SF, Chao DM, Wei W, Ye L, Young RA, Livingston DM, Parvin JD . 1997a Proc. Natl. Acad. Sci. USA 94: 5605–5610

  • Scully R, Chen J, Plug A, Xiao Y, Weaver D, Feunteun J, Ashley T, Livingston DM . 1997b Cell 88: 265–275

  • Shao N, Chai Y, Cui JQ, Wang N, Aysola K, Reddy ES, Rao VN . 1998 Oncogene 17: 527–532

  • Shao N, Chai YL, Shyam E, Reddy P, Rao VN . 1996 Oncogene 13: 1–7

  • Shore P, Sharrocks AD . 1995 Nucleic Acids Res. 23: 4698–4706

  • Somasundaram K, Zhang H, Zeng YX, Houvras Y, Peng Y, Wu GS, Licht JD, Weber BL, El-Deiry WS . 1997 Nature 389: 187–190

  • Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, Timmerman MM, Brody LC, Tucker MA . 1997 N. Engl. J. Med. 336: 1401–1408

  • Thompson ME, Jensen RA, Obermiller PS, Page DL, Holt JT . 1995 Nat. Genet. 9: 444–450

  • Wang H, Shao N, Ding QM, Cui J, Reddy ES, Rao VN . 1997 Oncogene 15: 143–157

  • Wang Q, Zhang H, Kajino K, Greene MI . 1998 Oncogene 17: 1939–1948

  • Wasylyk B, Hagman J, Gutierrez-Hartmann A . 1998 Trends Biochem. Sci. 23: 213–216

  • Whitmarsh AJ, Shore P, Sharrocks AD, Davis RJ . 1995 Science 269: 403–407

  • Wilson CA, Payton MN, Elliott GS, Buaas FW, Cajulis EE, Grosshans D, Ramos L, Reese DM, Slamon DJ, Calzone FJ . 1997 Oncogene 14: 1–16

  • Wu LC, Wang ZW, Tsan JT, Spillman MA, Phung A, Xu XL, Yang MC, Hwang LY, Bowcock AM, Baer R . 1996 Nat. Genet. 14: 430–440

  • Yates PR, Atherton GT, Deed RW, Norton JD, Sharrocks AD . 1999 EMBO J. 18: 968–976

  • Yu X, Wu LC, Bowcock AM, Aronheim A, Baer R . 1998 J. Biol. Chem. 273: 25388–25392

  • Zhang H, Somasundaram K, Peng Y, Tian H, Bi D, Weber BL, El-Deiry WS . 1998 Oncogene 16: 1713–1721

Download references

Acknowledgements

We thank T Kouzarides for GAL4 reporter and expression plasmids, T Curran for the c-Fos plasmid, R Treisman for SAP1a plasmid, J Gioanne for the CAL-51 cell line, RJ Davis for pSRE×2 luciferase reporter plasmid and NG Ahn for pCMV-MEK-DN plasmid. We thank L Boyer for secretarial assistance. We also thank the other members of Rao and Reddy laboratories for their help. This work was supported by NIH grant RO1CA57322 and a clinical research infrastructure award from MCP Hahnemann University to VN Rao; U.S. Army Medical Research grant DAMD17-94-J-4280 to VN Rao; NIH grants RO1CA85343 and RO1CA58642 to ESP Reddy and U.S. Army Medical Research Grant DAMD17-99-1-9060 to ESP Reddy.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Chai, Y., Chipitsyna, G., Cui, J. et al. c-Fos oncogene regulator Elk-1 interacts with BRCA1 splice variants BRCA1a/1b and enhances BRCA1a/1b-mediated growth suppression in breast cancer cells. Oncogene 20, 1357–1367 (2001). https://doi.org/10.1038/sj.onc.1204256

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1204256

Keywords

  • c-Fos
  • BRCA1/BRCA1a/1b
  • Elk-1
  • growth suppression
  • breast cancer
  • protein–protein interaction

Further reading

Search

Quick links